Integer (NYSE:ITGR) Price Target Raised to $145.00 at Bank of America

Integer (NYSE:ITGR) had its target price raised by Bank of America from $135.00 to $145.00 in a report published on Tuesday, Benzinga reports. Bank of America currently has a buy rating on the medical equipment provider’s stock.

A number of other analysts have also weighed in on ITGR. Benchmark reissued a buy rating and issued a $130.00 price objective on shares of Integer in a research report on Friday, August 2nd. Truist Financial increased their price target on Integer from $137.00 to $145.00 and gave the stock a buy rating in a report on Tuesday. Finally, Oppenheimer began coverage on Integer in a report on Tuesday, July 16th. They set an outperform rating and a $135.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $137.29.

Integer Trading Down 2.2 %

Shares of NYSE ITGR opened at $127.19 on Tuesday. The stock has a market capitalization of $4.26 billion, a P/E ratio of 44.01, a PEG ratio of 1.87 and a beta of 1.09. Integer has a 1-year low of $69.40 and a 1-year high of $131.87. The business’s 50 day moving average is $123.37 and its two-hundred day moving average is $119.31. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.29 and a quick ratio of 1.96.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, topping the consensus estimate of $1.24 by $0.06. Integer had a net margin of 6.31% and a return on equity of 11.48%. The company had revenue of $436.20 million during the quarter, compared to analyst estimates of $437.00 million. During the same period in the previous year, the firm earned $1.14 earnings per share. Integer’s quarterly revenue was up 9.0% compared to the same quarter last year. As a group, research analysts expect that Integer will post 5.31 EPS for the current year.

Insiders Place Their Bets

In other news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the transaction, the director now owns 2,280 shares in the company, valued at $272,824.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Integer

Hedge funds and other institutional investors have recently modified their holdings of the business. Quest Partners LLC lifted its holdings in Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 332 shares during the period. GAMMA Investing LLC lifted its stake in shares of Integer by 60.9% during the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 142 shares during the last quarter. Headlands Technologies LLC bought a new stake in Integer during the first quarter valued at about $106,000. Innealta Capital LLC purchased a new position in Integer in the second quarter valued at about $110,000. Finally, Hancock Whitney Corp bought a new position in Integer in the first quarter worth about $203,000. 99.29% of the stock is currently owned by institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.